Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a hormone supplement ease lung pressure in COPD?

NCT ID NCT00581087

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily dose of the hormone DHEA can help adults with COPD who also have high blood pressure in their lungs. Sixty participants took either DHEA or a placebo for one year. Researchers measured how far they could walk in six minutes and checked heart and lung function to see if DHEA improves exercise capacity and blood flow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dehydroepiandrosterone (DHEA)
What this could lead to
If it works, this could point toward a new treatment option for pulmonary hypertension in people with COPD, potentially improving exercise capacity and heart function.
What could go wrong
This is a small, completed Phase 3 trial with only 60 participants, so results may not apply to everyone. DHEA may not improve symptoms or could cause side effects like hormonal changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jan 2007

Finished

Jun 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old and ≤ 75 years old (\*) * Chronic Obstructive Pulmonary Disease with FEVs/VC \< 70% (\*\*) * Respiratory pulmonary hypertension with mean pulmonary arterial pressure ≥ 25 mmHg (\*\*) related to normal pulmonary capillary pressure assessed by catheterization of the right side of the heart (pulmonary capillary wedge pressure ≤12mmHg) * PO2 ≤ 60 mmHg assessed by arterial gazometry at ease (\*\*) or PO2 \> 60 mmHg, but related with high hypoxemia after exercise (six-minute walk test ) * Oxygenotherapy more than 6 months before pre-screening * Written informed consent (\*) Inclusion of young adults concerns COPD related to asthma or cystic fibrosis (\*\*) Criteria assessed from last health check or the last exams for COPD diagnosis Exclusion Criteria: * clinical instability and/or respiratory exacerbation within the previous three months * clinical instability and/or respiratory exacerbation dangerous for catheterization * Pregnancy (ßHCG \> 20 UI /l) or breastfeeding on going * General corticotherapy \> 0,5 mg/kg/day prédnisolone equivalent * Hepatic insufficiency (TP \< 50%) or renal insufficiency (creatininemia \> 130 µmol/l) or diabetes mellitus type I or II (treated by oral antidiabetic or insulin) * Left-heart failure (coronary heart disease and/or left valvulopathy) * High level of prostatic specific antigen (PSA) (\> 2,5ng/ml) * Cancer antecedent or treatment on going

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease Hypertension, pulmonary

Contacts and locations

Locations

  • APHP hospital Antoine Béclère GHU sud

    Clamart, 92141, France

  • University Hospital, Bordeaux

    Bordeaux, France

  • University Hospital, Limoges

    Limoges, France

  • University Hospital, Strasbourg

    Strasbourg, France

  • University Hospital, Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.